The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 23, 2006

Filed:

Aug. 09, 2000
Applicants:

Elizabeth C. Arner, West Grove, PA (US);

Timothy C. Burn, Hockessin, DE (US);

Robert A. Copeland, Hockessin, DE (US);

Carl P. Decicco, Newark, DE (US);

Ruiqin Liu, Hockessin, DE (US);

Ronald Magolda, Wallingford, PA (US);

Michael Pratta, Glassboro, NJ (US);

Kimberly A. Solomon, Landenburg, PA (US);

Micky D. Tortorella, Newark, DE (US);

James M. Trzaskos, Boothwyn, PA (US);

Fude Yang, Wilmington, DE (US);

Inventors:

Elizabeth C. Arner, West Grove, PA (US);

Timothy C. Burn, Hockessin, DE (US);

Robert A. Copeland, Hockessin, DE (US);

Carl P. Decicco, Newark, DE (US);

Ruiqin Liu, Hockessin, DE (US);

Ronald Magolda, Wallingford, PA (US);

Michael Pratta, Glassboro, NJ (US);

Kimberly A. Solomon, Landenburg, PA (US);

Micky D. Tortorella, Newark, DE (US);

James M. Trzaskos, Boothwyn, PA (US);

Fude Yang, Wilmington, DE (US);

Assignee:

Bristol-Myers Squibb Pharma Comp., Princeton, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/00 (2006.01);
U.S. Cl.
CPC ...
Abstract

The invention is directed to the family of aggrecan degrading metallo proteases (ADMPs) that exhibit the ability to cleave the aggrecan core protein between amino acid residues Glu-Ala. The invention encompasses the nucleic acids encoding such enzymes, processes for production of recombinant ADMPs, compositions containing such enzymes, and the use of these enzymes in various assays and for the development of novel inhibitors for use as therapies for diseases involving aggrecanase-mediated degradation of cartilage or other aggrecanase-associated diseases.


Find Patent Forward Citations

Loading…